QurCan to participate in Novo Nordisk's program

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

QurCan Therapeutics has been selected to participate in Novo Nordisk's Co-Creation Greenhouse Program. Anchored through the Novo Nordisk Bio Innovation Hub, this collaboration provides QurCan with funding and deep scientific and technical expertise in translational and drug development.

QurCan Therapeutics is an OBIO® member, an alumnus of the BDSP™, CAAP® and HealthMINT™ programs and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

New technology aims to improve access to cancer care
Next

Vasomune Therapeutics and AnGes drug candidate AV-001 receives positive recommendation from the IDSMB for AV001-004 phase 2a study